|
|
|
|
|
|
|
|
23.05.25 - 00:01
|
XFRA: DIVIDEND/INTEREST INFORMATION - 26.05.2025 - EQUBF_01 (XETRA)
|
|
Das Instrument DSYA FR0014003TT8 DASSAULT SYS SE INH.EO0,1 EQUITY wird cum Dividende/Zinsen gehandelt am 23.05.2025 und ex Dividende/Zinsen am 26.05.2025
The instrument DSYA FR0014003TT8 DASSAULT SYS SE INH.EO0,1 EQUITY has its pre-dividend/interest day on 23.05.2025 and its ex-dividend/interest day on 26.05.2025...
|
|
|
|
|
|
|
|
|
|
19.03.25 - 07:03
|
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience With Investment in Click Therapeutics for Digital Therapeutics Beyond Clinical Trials (Business Wire)
|
|
This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes' role in the industry's transformation
Click Therapeutics will gain access to Dassault Systèmes' global presence and expertise to support the development of new therapies
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)--#3DEXPERIENCE--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced its investment in Click Therapeutics, a leader in prescription digital therapeutics and software-enhanced drug therapies. The transaction advances Dassault Systèmes' transformation of the patient experience in life sciences and healthcare through end-to-end technology solutions used across the healthcare ecosystem.
The transaction strengthens the existing relationship between Dassault Systèmes' MEDIDATA brand and Click Therapeutics, helping to improve patient engagement - post-trial through commercialization - and advancing the Patient Experience to deliver end-to-end technology solutions across the...
|
|
|
18.03.25 - 16:03
|
Andea achieves Dassault Systèmes Gold Partner status (PR Newswire)
|
|
BREA, Calif., March 18, 2025 /PRNewswire/ -- Andea, a global leader in digital transformation, including consulting and implementation services, proudly announces its achievement of Dassault Systèmes Gold Partner status. This recognition solidifies Andea's position as a trusted reseller......
|
|
|